CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer

Shawn F. Johnson, Cristina Cruz, Ann Katrin Greifenberg, Sofia Dust, Daniel G. Stover, David Chi, Benjamin Primack, Shiliang Cao, Andrea J. Bernhardy, Rhiannon Coulson, Jean Bernard Lazaro, Bose Kochupurakkal, Heather Sun, Christine Unitt, Lisa A. Moreau, Kristopher A. Sarosiek, Maurizio Scaltriti, Dejan Juric, José Baselga, Andrea L. RichardsonScott J. Rodig, Alan D. D'Andrea, Judith Balmaña, Neil Johnson, Matthias Geyer, Violeta Serra, Elgene Lim, Geoffrey I. Shapiro

    Research output: Contribution to journalArticleResearchpeer-review

    126 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer'. Together they form a unique fingerprint.

    Medicine & Life Sciences

    Chemical Compounds